Literature DB >> 18725854

Utilities should not be multiplied: evidence from the preference-based scores in the United States.

Alex Z Fu1, Michael W Kattan.   

Abstract

OBJECTIVE: Several estimators exist when average utility scores are not available for patient populations with multiple disease conditions. The multiplicative estimator is a widespread choice among them. Our study is to empirically test the accuracy of the multiplicative estimator and compare it with other estimators.
METHODS: The Medical Expenditure Panel Survey (MEPS) has a nationally representative sample of the US civilian noninstitutionalized population. Using the pooled 2001 and 2003 data, a sample of 40,846 individuals with EQ-5D index scores were categorized into 238 disease condition categories. The study focus was the difference between the estimated and the observed mean scores for each comorbid pair, with the observed one presumed to be the true value.
RESULTS: The scores estimated by multiplying the 2 mean scores of the corresponding disease conditions on average had a statistically significantly larger difference (P < 0.0001) from the observed ones (-0.094) than simply picking the smaller mean of the 2 paired conditions (difference = 0.025), the larger mean of the 2 (difference = 0.071), the average of the 2 means (difference = 0.048), or the mean of the condition with smaller sample size of the pair (difference = 0.049). However, the multiplicative estimator performed better than the additive estimator (sum of the means minus 1, difference = -0.123).
CONCLUSIONS: Multiplication is not a good estimate when the average utility score for patients with 2 disease conditions is not readily available. The lower of the 2 utility scores had the least error among those estimators that we compared. Further research with an experimental design is warranted before a specific alternative can be firmly recommended.

Entities:  

Mesh:

Year:  2008        PMID: 18725854     DOI: 10.1097/MLR.0b013e3181791a9c

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  16 in total

1.  Perspective on the cost-effectiveness of transapical aortic valve implantation in high-risk patients: Outcomes of a decision-analytic model.

Authors:  Hemal Gada; Shikhar Agarwal; Thomas H Marwick
Journal:  Ann Cardiothorac Surg       Date:  2012-07

2.  Sourcing quality-of-life weights obtained from previous studies: theory and reality in Korea.

Authors:  SeungJin Bae; Eun Young Bae; Sang Hee Lim
Journal:  Patient       Date:  2014       Impact factor: 3.883

Review 3.  Estimating Health State Utility Values for Comorbidities.

Authors:  Roberta Ara; John Brazier
Journal:  Pharmacoeconomics       Date:  2017-12       Impact factor: 4.981

4.  Individualized Glycemic Control for U.S. Adults With Type 2 Diabetes: A Cost-Effectiveness Analysis.

Authors:  Neda Laiteerapong; Jennifer M Cooper; M Reza Skandari; Philip M Clarke; Aaron N Winn; Rochelle N Naylor; Elbert S Huang
Journal:  Ann Intern Med       Date:  2017-12-12       Impact factor: 25.391

5.  Joint Utility Estimators in Substance Use Disorders.

Authors:  Eve Wittenberg; Jeremy W Bray; Achamyeleh Gebremariam; Brandon Aden; Bohdan Nosyk; Bruce R Schackman
Journal:  Value Health       Date:  2016-11-17       Impact factor: 5.725

6.  Measuring benefits of opioid misuse treatment for economic evaluation: health-related quality of life of opioid-dependent individuals and their spouses as assessed by a sample of the US population.

Authors:  Eve Wittenberg; Jeremy W Bray; Brandon Aden; Achamyeleh Gebremariam; Bohdan Nosyk; Bruce R Schackman
Journal:  Addiction       Date:  2015-12-17       Impact factor: 6.526

Review 7.  A systematic review of utility values for chemotherapy-related adverse events.

Authors:  Fatiha H Shabaruddin; Li-Chia Chen; Rachel A Elliott; Katherine Payne
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

8.  Joint assessment of intended and unintended effects of medications: an example using vascular endothelial growth factor inhibitors for neovascular age-related macular degeneration.

Authors:  Adrian R Levy; Shelagh Szabo; Andrew Briggs; Andreas Pleil; Alison Davie; Gergana Zlateva; Jonathan Javitt
Journal:  J Ophthalmol       Date:  2010-02-16       Impact factor: 1.909

9.  Population preference values for treatment outcomes in chronic lymphocytic leukaemia: a cross-sectional utility study.

Authors:  Kathleen M Beusterien; John Davies; Michael Leach; David Meiklejohn; Jessica L Grinspan; Alison O'Toole; Steve Bramham-Jones
Journal:  Health Qual Life Outcomes       Date:  2010-05-18       Impact factor: 3.186

10.  Societal preference values for advanced melanoma health states in the United Kingdom and Australia.

Authors:  K M Beusterien; S M Szabo; S Kotapati; J Mukherjee; A Hoos; P Hersey; M R Middleton; A R Levy
Journal:  Br J Cancer       Date:  2009-07-14       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.